Navigation Links
Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®

SAN DIEGO, April 24, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.


The gold standard for determining drug therapy benefit against infectious disease targets is to measure changes in patient viral load, otherwise known as the amount of virus that is detectable in circulation.  Specific to Hepatitis C virus (HCV), the best predictor of whether a treated patient will achieve a long-term viral cure is the period of time it takes to first achieve undetectable viral load.  We recently disclosed that the administration of Hemopurifer® therapy during the first three days of peginterferon+ribavirin (PR) drug therapy resulted in observations of immediate (IVR) and rapid virologic responses (RVR) in hard-to-treat genotype-1 patients.  IVR is a 2-log or 100 fold reduction of HCV viral load at day-7.  Such a response correlates with 90+% viral cure rates, yet is observed in less than 5% of patients who receive PR therapy alone.  RVR is defined as undetectable HCV viral load at day-30 of treatment and correlates with viral cure rates of 86.2%, which is observed in only 10.35% of patients who initiate PR therapy. 

In this note, I will discuss an unprecedented data point that further validates the potential of Hemopurifier® therapy to improve the benefit of current interferon-based and emerging all-antiviral drug regimens.  This same data point also provides further evidence that may help to explain our recent IVR and RVR treatment observations.

As the result of a collaborative discussion with reviewers at the Center for Devices and Radiological Health (the FDA branch responsible for approving medical devices in the US), our researchers initiated an effort to establish a protocol that would quantify the amount of HCV captured within our Hemopurifier® during a single treatment application.  This would first entail a post-treatment preparation for each Hemopurifier®, which would then need to be frozen until ready for shipment on dry ice.  This process is still being perfected as two of the first three cartridges analyzed were badly cracked.  The next step was to establish a repeatable protocol methodology that would allow biological fluid to be eluted from within the Hemopurifier® so that PCR, the standard for measuring viral copies, could be utilized to validate and quantify the capture of HCV during treatment.  The results were compelling.

In the two cracked cartridges referenced above, our researchers recovered and measured the capture of 145 million and 353 million copies of HCV.  However, when the fully intact Hemopurifier® was analyzed, our researchers recovered and measured that 300 billion (300,000,000,000) copies of HCV had been captured during a single six-hour treatment.  For those viruses captured, the possibility of continued progeny virus replication was eliminated.  I applaud our research team for establishing this unprecedented data point, which defines the contribution our Hemopurifier® can provide to current and future HCV treatment regimens.  Additionally, this data point serves as a model for capture capacity of other disease enhancing particles, whether they be associated with cancer, sepsis or other viral conditions. 

About Aethlon Medical

The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to capture hepatitis c virus, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.



James A. Joyce
Chairman and CEO
858.459.7800 x301

Jim Frakes
Chief Financial Officer
858.459.7800 x300

John P. Salvador
Director, Communications
858.459.7800 x307


SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
2. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
3. Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
4. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
5. Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs
6. Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program
7. Aethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
8. Aethlon Medical Reestablishes Biodefense Programs
9. Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships
10. Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors
11. Aethlon Medical Names Rod Kenley President
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
Breaking Medicine News(10 mins):